EPOCH 40: BIOTECH MARKET RESEARCH $VSTM

Versastem

Save the date—Verastem (VSTM) is set to shake things up! Results from the pivotal Phase 2 RAMP-201 Avutometinib +/- Defactinib trial in Low-Grade Serous Ovarian Cancer (LGSOC) are just around the corner. With options pricing signaling a staggering 170% implied volatility, the market is anticipating major action. Stay tuned, this could be a defining moment!

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

ALERT: Phase 2 RAMP-201 Avutometinib +/- Defactinib trial in Low-Grade Serous Ovarian Cancer (LGSOC)

DATE: mid-October

IMPLIED VOLATILITY: +/- 155%

BACKGROUND: